Compare Inovio Pharmaceuticals Inc (INO) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M). The key difference: T-Rex 2X Long MSTR Daily Target ETF is far larger — about 7.2× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| INO | MSTU | |
|---|---|---|
Market Cap | $112.19M | $809.00M |
Volume | 3,201,278 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.60 | $432.00 |
52-Week Low | $0.66 | $14.60 |
Typical Hold Time | 43 Days | 18 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
MSTU is trading at $38.33, down 2.84% on the day, with a bearish technical outlook as moving averages signal selling pressure. The stock recently underwent a 10:1 reverse stock split effective August 24, 2026, and declared a $0.29 dividend payable August 26, 2026. Key support levels are at $37 and $35, while resistance sits at $40 and $41.
The outlook remains cautious due to the bearish technical setup and lack of current fundamental data. Investment opportunities hinge on the company's ability to demonstrate improved financial performance post-reverse split, while risks include continued technical weakness and potential volatility from the leveraged ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
